Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

3SBio’s Q3 Hurt by Lehman Bankruptcy

publication date: Nov 3, 2008

3SBio Inc. announced a $2.7 million writedown as a consequence of the US financial crisis. The company invested in $3 million of Floating Rate Notes due January 21, 2009 that are subject to the credit of Lehman Brothers. As a consequence of the Lehman Brothers bankruptcy, the notes have been given a value of $300,000. 3SBio made the announcement as part of its preliminary Q3 unaudited results. The company said its Q3 revenues climbed 22% to 68.2 million RMB ($10.0 million). However, because of the charge, net income dropped to 1.9 million RMB ($0.3 million), or $0.01 per ADS. More details...

Stock Symbol: (NSDQ: SSRX)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital